Role of the Long Intergenic Non-Protein-Coding RNA 1278/miR-185-5p/Cystatin SN Axis in Laryngeal Cancer Cells.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
03
2022
revised:
25
03
2022
accepted:
04
04
2022
entrez:
2
5
2022
pubmed:
3
5
2022
medline:
3
5
2022
Statut:
epublish
Résumé
Laryngeal cancer accounts for 25%-30% of tumors in the head and neck. Cystatin SN (CST1) was revealed to show upregulated expression in this cancer, while its functions and upstream pathway remain unknown and need investigation. The current study was designed to solve this problem. We designed short hairpin RNAs targeting CST1 for the loss-of-function assays to probe the influences of CST1 in laryngeal cancer cell proliferation and motility. The upstream competitive endogenous RNA pattern of CST1 was searched using bioinformatics analysis and confirmed by luciferase reporter assays. The experimental results demonstrated that CST1 is a tumor facilitator in laryngeal cancer by stimulating cellular proliferative, migrative, and invasive abilities. CST1 is regulated by the long intergenic non-protein-coding RNA 1278 (LINC01278)/miR-185-5p axis. LINC01278 knockdown and miR-185-5p overexpression exert the same functions as CST1 knockdown to repress cancer cell proliferation, migration, and invasion. In conclusion, LINC01278 plays an oncogenic role in laryngeal cancer by suppressing miR-185-5p to enhance CST1 expression, which enriches the molecular mechanism for the carcinogenesis of laryngeal cancer.
Identifiants
pubmed: 35498540
doi: 10.1155/2022/6406943
pmc: PMC9050325
doi:
Types de publication
Journal Article
Langues
eng
Pagination
6406943Informations de copyright
Copyright © 2022 Bin Shen et al.
Déclaration de conflit d'intérêts
The authors declare that there are no competing interests in this study.
Références
Cell Death Dis. 2017 Mar 16;8(3):e2682
pubmed: 28300829
Oncogene. 2020 Jun;39(23):4538-4550
pubmed: 32372060
Eur Arch Otorhinolaryngol. 2016 Jun;273(6):1481-7
pubmed: 26879991
Nat Commun. 2021 Dec 17;12(1):7335
pubmed: 34921160
Life Sci. 2018 Nov 15;213:9-17
pubmed: 30308183
BMC Cancer. 2021 Jun 15;21(1):705
pubmed: 34130645
PLoS One. 2016 Dec 29;11(12):e0169232
pubmed: 28033431
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7
pubmed: 24297251
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
FEBS Open Bio. 2021 Jun 8;:
pubmed: 34102026
Auris Nasus Larynx. 2013 Oct;40(5):481-6
pubmed: 23462687
J Mol Med (Berl). 2017 Aug;95(8):873-886
pubmed: 28523467
Cancer Manag Res. 2021 Feb 24;13:1901-1907
pubmed: 33658852
Cancer Biol Ther. 2019;20(6):826-836
pubmed: 30907227
Biomed Biochim Acta. 1986;45(11-12):1363-74
pubmed: 3555466
Cancer Cell Int. 2021 Jul 17;21(1):380
pubmed: 34273985
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1366-1378
pubmed: 33629307
Genes (Basel). 2018 Jun 18;9(6):
pubmed: 29912172
EMBO Rep. 2017 Oct;18(10):1837-1853
pubmed: 28887321
Trends Mol Med. 2018 Mar;24(3):257-277
pubmed: 29449148
J Cell Physiol. 2020 Jan 29;:
pubmed: 31994731
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
J Biochem Mol Toxicol. 2021 Oct;35(10):e22878
pubmed: 34472153
Open Med (Wars). 2020 Mar 26;15:240-248
pubmed: 32266320
Front Cell Dev Biol. 2021 Apr 21;9:670019
pubmed: 33968941